Abbott (ABT) Settles with U.S. Over Depakote; Will Pay ~$1.6B in Fines

Article Stock Quotes (1) Comments (0)

Abbott (NYSE: ABT) has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing practices relating to its neurologic medication Depakote. The settlement results from a four-year-old investigation into past sales activities that began in 1998 involving this product. Abbott cooperated fully with the government during its investigation.

Abbott will pay $800 million to resolve civil allegations split among federal and state governments, $700 million for a criminal penalty, and $100 million to states to resolve consumer protection matters. These amounts were previously reserved in anticipation of today's agreement.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Acacia Research (ACTG) Enters Settlement with Red Hat (RHT)
• Abbott (ABT) Receives CE Mark for XIENCE Coronary Stent System
• Abbott to Present at Deutsche Bank 38th Annual Health Care Conference

Create E-mail Alert Related Categories

Corporate News, Litigation

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?